Literature DB >> 6092279

In vitro activity of fosfomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

W Graninger, T Leitha, M Havel, A Georgopoulos.   

Abstract

The in vitro antibacterial activity of fosfomycin was compared to that of oxacillin, cefazolin, ceftriaxone and vancomycin against isolates of Staphylococcus aureus from patients treated at the University of Vienna General Hospital. Of 211 strains, 104 were methicillin-susceptible and 107 were methicillin-resistant. Fosfomycin inhibited over 90% of the strains at concentrations of less than or equal to 64 mg/l, independent of methicillin susceptibility or resistance. The minimal bactericidal concentrations (MBC) were one dilution above the minimal inhibitory concentrations (MIC). Vancomycin showed activity similar to fosfomycin while other beta-lactam antibiotics such as oxacillin, cefazolin and ceftriaxone were inactive against methicillin-resistant S. aureus. Fosfomycin at a high dosage seems to be a potential drug for the treatment of infections due to methicillin-resistant S. aureus.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6092279     DOI: 10.1007/bf01645964

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  9 in total

1.  New method for detecting in vitro inactivation of penicillins by Haemophilus influenzae and Staphlycoccus aureus.

Authors:  W S Lee; L Komarmy
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

2.  [Conditions influencing the activity of fosfomycin in vitro (author's transl)].

Authors:  R Haag; W Vömel
Journal:  Immun Infekt       Date:  1979-12

3.  The evolution of the sensitivity to fosfomycin over the past two years.

Authors:  M Gobernado; M Santos; N Diosdado; F Pérez
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

4.  Effectiveness of cefamandole against methicillin-resistant strains of Staphylococcus aureus in vitro and in experimental infections.

Authors:  A Hirschl; G Stanek; M Rotter
Journal:  J Antimicrob Chemother       Date:  1984-05       Impact factor: 5.790

5.  Vancomycin therapy for methicillin-resistant Staphylococcus aureus.

Authors:  T C Sorrell; D R Packham; S Shanker; M Foldes; R Munro
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

6.  The emergence of methicillin-resistant Staphylococcus aureus infections in United States hospitals. Possible role of the house staff-patient transfer circuit.

Authors:  R W Haley; A W Hightower; R F Khabbaz; C Thornsberry; W J Martone; J R Allen; J M Hughes
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

7.  Gentamicin- and methicillin-resistant, clinical isolates of Staphylococcus aureus: comparative in vitro and in vivo efficacy of alternative antimicrobial drugs.

Authors:  W H Traub; M Spohr; D Bauer
Journal:  Chemotherapy       Date:  1984       Impact factor: 2.544

8.  Pharmacokinetics of fosfomycin.

Authors:  W M Kirby
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

9.  [Clinical experience with fosfomycin in urinary tract infections (author's transl)].

Authors:  H J Peters; R Eicher
Journal:  MMW Munch Med Wochenschr       Date:  1981-05-01
  9 in total
  4 in total

Review 1.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

2.  Activity of 18 antimicrobial agents against multi-resistant strains of Staphylococcus aureus isolated from intensive care patients.

Authors:  D Duncker; U Ullmann
Journal:  Infection       Date:  1985 Sep-Oct       Impact factor: 3.553

3.  The microbiological efficacy of the combination of fosfomycin and vancomycin against clinically relevant staphylococci.

Authors:  S Gatermann; E Schulz; R Marre
Journal:  Infection       Date:  1989 Jan-Feb       Impact factor: 3.553

4.  Efficacy of penicillin G, flucloxacillin, cefazolin, fusidic acid, vancomycin, rifampicin and fosfomycin in muscular infections in mice due to Staphylococcus aureus.

Authors:  R Haag
Journal:  Infection       Date:  1986 Jan-Feb       Impact factor: 3.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.